

Regional Drugs Testing Laboratory

Directorate General of Health Services, Guwahati (India) - 78/1022 Tug

Fax: 0361-2338555/2330555 Phone No.0361 2338555

Email:rdtlguwahati@cdsco.nic.in

FORM 13 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

Name of Inspector from whom received

: Mr. R. Vanlalruata, Asst. Director (F and D)

ASSISTANT DIRECTOR(F&D)

OFFICE OF CHIEF MEDICAL OFFICER, AIZAWL,

MIZORAM, PIN-769017

Serial No. and date of Inspector's memorandum

: MZ/24/A' E'/22/IPA, 17-DEC-2024

Number of Sample

: NIL

Date of receipt

: 02-JAN-2025

Names of drugs purporting to be contained in the sample : Cefixime Dispersible Tablets IP PANCEF™- O 100 mg

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024- 25/1867	GUW/LS/2024- 25/1889	T242403	Jun-2024	May-2026	Aglowmed Ltd., 51, Raipur, Roorkee- 247661, H.O.: 702- A, Poonam Chambers, Dr. A. B Road, Worli, Mumbai-
		1 / / /			400018, INDIA.

Condition of seals on

[the packet or on portion of sample or container]

Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector.

7. Result of test or analysis with protocols or test or analysis applied

Please see below

Date of Testing:

From 23-Jan-2025 To 12-Mar-2025

COMPOSITION

Each Dispersible Uncoated Tablet Contains:

Cefixime IP equivalent to anhydrous Cefixime 100 mg

Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	Limits	
1 Description		White, round, flat, having scored on one surface, uncoated tablets, in blister packing.	NA	
2	Identification	Gives positive test for Cefixime.	NA	
3	Average weight	0.3084 g	NA	
4	Disintegration	Complies. (Time taken for disintegration 23 seconds)	NMT 3 minutes	

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method

1 Cefixime eq. to anhydrous Cefixime	100 mg/Tablet	101.24	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 18-MAR-2025

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

------ END OF REPORT -----

